Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 11, 2017, Pages 1385-1395

  Kelly, Elizabeth A ^a   Esnault, Stephane ^a   Liu, Lin Ying ^a   Evans, Michael D ^a   Johansson, Mats W ^a   Mathur, Sameer ^a   Mosher, Deane F ^a   Denlinger, Loren C ^a   Jarjour, Nizar N ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Allergen challenge; IL 3 receptor; IL 5

Indexed keywords

MEPOLIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ASTHMA; BIOPSY; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHUS; DIAGNOSTIC IMAGING; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FLOW CYTOMETRY; HUMAN; MALE; METABOLISM; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; RESPIRATORY SYSTEM;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BIOPSY; BRONCHI; BRONCHOALVEOLAR LAVAGE FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILS; FLOW CYTOMETRY; HUMANS; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; RESPIRATORY SYSTEM;

EID: 85038128366     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201611-2234OC     Document Type: Article

References (57)

1. Volbeda F, Broekema M, Lodewijk ME, Hylkema MN, Reddel HK, Timens W, Postma DS, ten Hacken NH. Clinical control of asthma associates with measures of airway inflammation. Thorax 2013;68:19–24.
2. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715–1721.
3. Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin-5 monoclonal antibody. Clin Pharmacokinet 2011;50:215–227.
4. Keating GM. Mepolizumab: first global approval. Drugs 2015;75:2163–2169.
5. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoid–sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–1197.
6. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al.; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198–1207.
7. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973–984.
8. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O’Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985–993.
9. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–659.
10. Yancey SW, Ortega HG, Keene ON, Mayer B, Gunsoy NB, Brightling CE, Bleecker ER, Haldar P, Pavord ID. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J Allergy Clin Immunol 2017;139:1167–1175.e2.
11. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem 2014;289:17406–17415.
12. Persson C, Uller L. Theirs but to die and do: primary lysis of eosinophils and free eosinophil granules in asthma. Am J Respir Crit Care Med 2014;189:628–633.
13. Kelly EA, Liu LY, Esnault S, Quinchia Johnson BH, Jarjour NN. Potent synergistic effect of IL-3 and TNF on matrix metalloproteinase 9 generation by human eosinophils. Cytokine 2012;58:199–206.
14. 1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997; 17:326–333.
15. Kelly EA, Esnault S, Johnson SH, Liu LY, Malter JS, Burnham ME, Jarjour NN. Human eosinophil activin A synthesis and mRNA stabilization are induced by the combination of IL-3 plus TNF. Immunol Cell Biol 2016;94:701–708.
16. Esnault S, Kelly EA, Johansson MW, Liu LY, Han ST, Akhtar M, Sandbo N, Mosher DF, Denlinger LC, Mathur SK, et al. Semaphorin 7A is expressed on airway eosinophils and upregulated by IL-5 family cytokines. Clin Immunol 2014;150:90–100.
17. Spencer LA, Bonjour K, Melo RC, Weller PF. Eosinophil secretion of granule-derived cytokines. Front Immunol 2014;5:496.
18. Liu LY, Mathur SK, Sedgwick JB, Jarjour NN, Busse WW, Kelly EA. Human airway and peripheral blood eosinophils enhance Th1 and Th2 cytokine secretion. Allergy 2006;61:589–597.
19. 1 T lymphocytes. Clin Exp Allergy 2012;42:1756–1764.
20. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1b and 6 but not transforming growth factor-b are essential for the differentiation of interleukin 17–producing human T helper cells. Nat Immunol 2007;8:942–949.
21. Takatsu K. Interleukin-5 and its receptor molecules. In: Lee JJ, Rosenberg HF, editors. Eosinophils in health and disease. Oxford: Elsevier; 2013. pp. 97–103.
22. Johansson MW. Activation states of blood eosinophils in asthma. Clin Exp Allergy 2014;44:482–498.
23. Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, Jarjour NN, Busse WW, Kelly EA. Decreased expression of membrane IL-5 receptor a on human eosinophils. I. Loss of membrane IL-5 receptor a on airway eosinophils and increased soluble IL-5 receptor a in the airway after allergen challenge. J Immunol 2002;169:6452–6458.
24. Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, Jarjour NN, Busse WW, Kelly EAB. Decreased expression of membrane IL-5 receptor a on human eosinophils. II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 2002;169:6459–6466.
25. Gregory B, Kirchem A, Phipps S, Gevaert P, Pridgeon C, Rankin SM, Robinson DS. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor a-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor a expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor a expression. J Immunol 2003;170:5359–5366.
26. Calhoun WJ, Jarjour NN, Gleich GJ, Stevens CA, Busse WW. Increased airway inflammation with segmental versus aerosol antigen challenge. Am Rev Respir Dis 1993;147:1465–1471.
27. Kelly EA, Denlinger LC, Liu L, Mathur SK, Esnault S, DeLain LP, Schwantes EA, Cook EB, Stahl JL, Jarjour NN. Utilization of segmental bronchoprovocation to study the effect of anti–IL-5 (mepolizumab) on eosinophil phenotype and recruitment to the airway in subjects with atopic asthma [abstract]. Presented at the 7th International Eosinophil Society Symposium. June 21–25, 2011, Québec City, Canada.
28. Protheroe C, Woodruff SA, de Petris G, Mukkada V, Ochkur SI, Janarthanan S, Lewis JC, Pasha S, Lunsford T, Harris L, et al. A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2009;7:749–755.e11.
29. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963–974.
30. Hartnell A, Robinson DS, Kay AB, Wardlaw AJ. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology 1993;80:281–286.
31. Matsumoto K, Appiah-Pippim J, Schleimer RP, Bickel CA, Beck LA, Bochner BS. CD44 and CD69 represent different types of cell-surface activation markers for human eosinophils. Am J Respir Cell Mol Biol 1998;18:860–866.
32. Esnault S, Kelly EA, Schwantes EA, Liu LY, DeLain LP, Hauer JA, Bochkov YA, Denlinger LC, Malter JS, Mathur SK, et al. Identification of genes expressed by human airway eosinophils after an in vivo allergen challenge. PLoS One 2013;8:e67560.
33. Shen ZJ, Hu J, Esnault S, Dozmorov I, Malter JS. RNA Seq profiling reveals a novel expression pattern of TGF-b target genes in human blood eosinophils. Immunol Lett 2015;167:1–10.
34. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti–interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199–204.
35. Gauvreau GM, Ellis AK, Denburg JA. Haemopoietic processes in allergic disease: eosinophil/basophil development. Clin Exp Allergy 2009;39:1297–1306.
36. Ackerman SJ, Du J. Transcriptional regulation of eosinophil lineage commitment and differentiation. In: Lee JJ, Rosenberg HF, editors. Eosinophils in health and disease. Oxford: Elsevier; 2012. pp. 76–89.
37. Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, Kay AB, Denburg J. Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003;111:714–719.
38. Büttner C, Lun A, Splettstoesser T, Kunkel G, Renz H. Monoclonal anti–interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003;21:799–803.
39. Conus S, Straumann A, Simon HU. Anti–IL-5 (mepolizumab) therapy does not alter IL-5 receptor a levels in patients with eosinophilic esophagitis. J Allergy Clin Immunol 2009;123:269, author reply 269–270.
40. Stein ML, Villanueva JM, Buckmeier BK, Yamada Y, Filipovich AH, Assa’ad AH, Rothenberg ME. Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008;121:1473–1483, 1483.e1–1483.e4.
41. 2-integrins on circulating eosinophils after segmental antigen challenge. Clin Exp Allergy 2013;43:292–303.
42. Melo RC, Weller PF. Piecemeal degranulation in human eosinophils: a distinct secretion mechanism underlying inflammatory responses. Histol Histopathol 2010;25:1341–1354.
43. Ueki S, Melo RC, Ghiran I, Spencer LA, Dvorak AM, Weller PF. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood 2013;121:2074–2083.
44. Radonjic-Hoesli S, Wang X, de Graauw E, Stoeckle C, Styp-Rekowska B, Hlushchuk R, Simon D, Spaeth PJ, Yousefi S, Simon HU. Adhesion-induced eosinophil cytolysis requires the receptor-interacting protein kinase 3 (RIPK3)-mixed lineage kinase-like (MLKL) signaling pathway, which is counterregulated by autophagy. J Allergy Clin Immunol 2017 (In press)
45. Neves JS, Perez SA, Spencer LA, Melo RC, Reynolds L, Ghiran I, Mahmudi-Azer S, Odemuyiwa SO, Dvorak AM, Moqbel R, et al. Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Proc Natl Acad Sci USA 2008;105:18478–18483.
46. Neves JS, Radke AL, Weller PF. Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules. J Allergy Clin Immunol 2010; 125:477–482.
47. Gibson PG, Manning PJ, O’Byrne PM, Girgis-Gabardo A, Dolovich J, Denburg JA, Hargreave FE. Allergen-induced asthmatic responses: relationship between increases in airway responsiveness and increases in circulating eosinophils, basophils, and their progenitors. Am Rev Respir Dis 1991;143:331–335.
48. 1 eosinophil-lineage–committed cells in the lung. Immunology 2011;132:144–154.
49. Menzies-Gow AN, Flood-Page PT, Robinson DS, Kay AB. Effect of inhaled interleukin-5 on eosinophil progenitors in the bronchi and bone marrow of asthmatic and non-asthmatic volunteers. Clin Exp Allergy 2007;37:1023–1032.
50. Sehmi R, Smith SG, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, Prazma CM, Ortega H, Martin JG, Nair P. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clin Exp Allergy 2016;46:793–802.
51. Fanat AI, Thomson JV, Radford K, Nair P, Sehmi R. Human airway smooth muscle promotes eosinophil differentiation. Clin Exp Allergy 2009;39:1009–1017.
52. Smith SG, Chen R, Kjarsgaard M, Huang C, Oliveria JP, O’Byrne PM, Gauvreau GM, Boulet LP, Lemiere C, Martin J, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol 2016;137:75–86.e78.
53. H2 cytokine–mediated immunity and inflammation at mucosal surfaces. Mucosal Immunol 2015;8:701–711.
54. Braccioni F, Dorman SC, O’Byrne PM, Inman MD, Denburg JA, Parameswaran K, Baatjes AJ, Foley R, Gauvreau GM. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J Allergy Clin Immunol 2002;110:96–101.
55. Ortega H, Chupp G, Bardin P, Bourdin A, Garcia G, Hartley B, Yancey S, Humbert M. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J 2014;44: 239–241.
56. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013;19:977–979.
57. Denlinger LC, Sorkness RL, Lee WM, Evans MD, Wolff MJ, Mathur SK, Crisafi GM, Gaworski KL, Pappas TE, Vrtis RF, et al. Lower airway rhinovirus burden and the seasonal risk of asthma exacerbation. Am J Respir Crit Care Med 2011;184:1007–1014.